1.The possible cost effectiveness of peripheral blood stem cell mobilization with clophosphamide and the late addition of G-CSF.
Young Joo MIN ; Sang We KIM ; Cheolwon SUH ; Jinny PARK ; Hyo Jung KIM ; Jeong Gyoon KIM ; Tae Won KIM ; Je Hwan LEE ; Sung Bae KIM ; Kyoo Hyung LEE ; Jung Shin LEE ; Woo Kun KIM ; Sang Hee KIM
Journal of Korean Medical Science 2000;15(1):49-52
The purpose of this study was to develop a cost-effective protocol for the mobilization of peripheral blood stem cells (PBSC) in patients with malignancy. Thirty consecutive patients were randomized to mobilize PBSC with the late addition of a standard 250 microg dose of G-CSF (Neutrogen) from day 8 or early addition of the same dose of G-CSF from day 2, following cyclophosphamide (CY) 4 g/m2. The median yield of CD34+ cells from evaluated patients was 7.87 x 10(6)/kg (range, 2.06-27.25), collected in a median of four apheresis (range, 2-9). Target CD34 + cell doses > or = 2.0 x 10(6)/kg were achieved in all patients able to be evaluated. There were no statistically significant differences in CD34+ cell yields or toxicities. Overall engraftment occurred with median days to neutrophils > or = 0.5 x 10(9)/L or platelets > 20 x 10(9)/L of 11 and 17 days, respectively. However, the duration of G-CSF administration was markedly shorter in the late use of G-CSF group than in the early use of G-CSF group, with a median of 9 days compared with 15 days (p>0.001). PBSC harvesting after priming with CY plus delayed use of G-CSF made it a safe and cost-effective procedure.
Adult
;
Aged
;
Antigens, CD34/metabolism
;
Antigens, CD34/immunology
;
Antineoplastic Agents, Alkylating/therapeutic use*
;
Antineoplastic Agents, Alkylating/adverse effects
;
Breast Neoplasms/therapy
;
Comparative Study
;
Cost-Benefit Analysis
;
Cyclophosphamide/therapeutic use*
;
Cyclophosphamide/adverse effects
;
Drug Administration Schedule
;
Female
;
Graft Survival
;
Granulocyte Colony-Stimulating Factor/therapeutic use*
;
Granulocyte Colony-Stimulating Factor/adverse effects
;
Hematopoietic Stem Cell Mobilization/methods*
;
Hematopoietic Stem Cell Mobilization/economics*
;
Hematopoietic Stem Cell Mobilization/adverse effects
;
Hematopoietic Stem Cell Transplantation
;
Hematopoietic Stem Cells/metabolism
;
Hematopoietic Stem Cells/immunology
;
Human
;
Lymphoma, Non-Hodgkin/therapy
;
Male
;
Middle Age
;
Multiple Myeloma/therapy
;
Sarcoma, Ewing's/therapy